saline solution, followed by seven 10-fold dilutions (1.5 ϫ 10 7 to 10 1 CFU/ml) also prepared in saline. All strains and dilutions were tested in triplicate. First, 600 l of each dilution was distributed into six wells of a microtiter plate (100 l/well). The ESwab and traditional swab triplicates were inoculated with 100 l of the dilution by placing each swab in one of the six wells of the prepared microtiter plate and allowing the swab to absorb the suspension for 10 s. After inoculation, the swabs were placed in their respective transport media. Prior to testing, the ESwab tube was vortex-mixed for 5 s and a 200-l aliquot from the transport medium was transferred either to Xpert MRSA lysis elution buffer or to BD Max MRSA sample buffer. Samples were vortex-mixed again for 5 s before being loaded onto a MRSA cartridge. ESwabs have greater absorption capacity than traditional swabs; thus, a volume Ͼ100 l would have been used if the ESwabs had been transferred directly to the assay buffer. For this reason, use of 200-l aliquots of the ESwab transport medium was initially chosen for this study. Traditional swabs were transferred directly into the assay buffer, and samples were vortex-mixed for 5 s before being loaded onto a MRSA cartridge. In total, 96 tests were performed for each real-time PCR assay, i.e., 48 tests using ESwabs and 48 tests using traditional swabs.
All results from dilutions of 1.5 ϫ 10 8 to 10 2 CFU/ml were positive for MRSA, in testing of both real-time PCR assays and swab types. The real-time PCR threshold cycle (C T ) values for the same dilutions but different swab types and real-time PCR assays were very similar to each other and, as expected, all C T values increased inversely proportionally to the bacterial concentration. C T values from triplicate tests were averaged, and results are presented in Fig. 1 . The dilutions of 1.5 ϫ 10 1 CFU/ml for cluster E and cluster AB showed positive results for the three traditional swab samples tested in the BD Max MRSA assay and for two of the three traditional swab samples tested in the Xpert MRSA assay. The same dilutions showed negative results for the three ESwab samples tested in the Xpert MRSA assay (cluster E) and for one of the three ESwab samples tested in the BD Max MRSA assay (cluster AB).
ESwab transfer to the ESwab medium results in 1:10 dilution of the initial inoculum, and only one-fifth of that solution was initially used for the real-time PCR assays. Therefore, to bring the aliquot concentration to at least one-half of the original inoculum concentration, these negative-result tests were repeated using 500 l of the ESwab liquid medium instead of 200 l. Positive results for MRSA were detected in all of the repeated tests (Table 1) . Ultimately, the limit of detection observed for ESwab samples using 500 l of the ESwab liquid medium (1.5 ϫ 10 1 CFU/ml) was in line with the analytical sensitivities of the Xpert MRSA (10 to 100 CFU/swab) and BD Max MRSA (273 to 645 CFU/swab) assays reported previously by the manufacturers (18, 19) .
Rapid accurate identification of MRSA isolates is essential not only for patient care but also for effective infection control programs to limit the spread of MRSA (1, 4, 6, 8, 20, 21 ). In the past few years, several commercially available rapid tests for the detection of MRSA directly from nasal swabs have been developed for use in clinical laboratories (9-12, 20, 21) . Real-Time PCR assays and other molecular tests are gaining popularity as screening tests for MRSA, especially because they are faster than culture methods in identifying patients who are candidates for contact precautions at the time of admission. Currently, there are two automated sample-in/answer-out walk-away real-time PCR assays for MRSA, i.e., the Cepheid Xpert MRSA assay performed on the GeneXpert system and the BD Max MRSA assay performed on the BD Max system. These assays are validated for use only with nasal specimens obtained with BBL CultureSwab Liquid Stuart (BD Diagnostics) or Venturi Transystem Swab Liquid Stuart (Copan Diagnostics) swabs (18, 19) . This means that, if further testing of the clinical specimen (strain typing, antibiotic susceptibility testing, or simply repeating the test) is required, then a second swab from the same patient must be collected.
Several studies have demonstrated the superior absorption and releasing capacity of ESwabs, in comparison with traditional swabs (13) (14) (15) (16) (17) (22) (23) (24) . The ESwab is a revolutionary concept because of its ability to offer what standard swabs cannot provide; ESwabs elute the entire sample into 1 ml of transport medium, providing identical aliquots of liquid sample suspension, which enables laboratories to determine and to validate the optimal specimen volumes (and therefore analyte amounts) for use in their assays. This is the first report of the use of the ESwab system as a collection system for the two sample-in/answer-out walkaway real-time PCR assays for MRSA. The results obtained showed that the ESwab system is a suitable alternative sample collection system for both the Xpert MRSA and BD Max MRSA assays. However, it is important to adjust the eluted sample volume to 500 l in order to obtain sensitivities similar to those obtained with traditional swabs. Moreover, it is possible to perform different tests (PCR assays and cultures) with the same col- 
